Taylor G N, Mays C W, Lloyd R D, Gardner P A, Talbot L R, McFarland S S, Pollard T A, Atherton D R, VanMoorhem D, Brammer D, Brammer T W, Ayoroa G, Taysum D H
Radiat Res. 1983 Sep;95(3):584-601.
Groups of C57BL/Do (black and albino) mice were injected with graded activities of 226Ra, 239Pu, 241Am, 249Cf, or 252Cf and were followed throughout life. Bone sarcoma was the principal radiation-induced end point, and the risks associated with average skeletal doses of the four transuranium radionuclides, relative to radium, were determined. The relative biological effectiveness (RBE) was calculated for each emitter by dividing its risk coefficient (bone sarcomas per 10(6) mouse-rad) by the risk coefficient for 226Ra. Combined data for males and females in both black and albino mice gave the following values +/- SD for the RBE relative to 226Ra = 1.0: 239Pu = 15.3 +/- 3.9, 241Am = 4.9 +/- 1.4, 249Cf = 5.0 +/- 1.4, and 252Cf = 2.6 +/- 0.8. About 70% of the tumors occurred in the axial skeleton, and the risk coefficient for females averaged about four times higher than for males when all five nuclides were included. The RBE of fission fragment irradiation from 252Cf for cancer induction, relative to alpha irradiation, for the combined data in all of the animals given 252Cf and 249Cf, was 0.02 +/- 0.28, in agreement with the calculated theoretical value of 0.03, based on the ratio of summed track lengths in tissue.
给几组C57BL/Do(黑色和白化)小鼠注射不同活度的镭-226、钚-239、镅-241、锎-249或锎-252,并对其进行终生跟踪。骨肉瘤是主要的辐射诱导终点,并确定了四种超铀放射性核素相对于镭的平均骨骼剂量相关风险。通过将每种发射体的风险系数(每10⁶小鼠拉德的骨肉瘤数)除以镭-226的风险系数,计算出每种发射体的相对生物效能(RBE)。黑色和白化小鼠中雄性和雌性的综合数据给出了相对于镭-226 = 1.0的RBE的以下值±标准差:钚-239 = 15.3 ± 3.9,镅-241 = 4.9 ± 1.4,锎-249 = 5.0 ± 1.4,锎-252 = 2.6 ± 0.8。约70%的肿瘤发生在中轴骨骼,当包括所有五种核素时,雌性的风险系数平均比雄性高约四倍。对于所有接受锎-252和锎-249的动物的综合数据,锎-252裂变碎片照射相对于α照射诱导癌症的RBE为0.02 ± 0.28,与基于组织中总径迹长度比计算的理论值0.03一致。